An Integrated Approach for the Rational Design of Nanovectors for Biomedical Imaging and Therapy

Advances in Genetics

Volumn 69, Issue C, 2010, Pages 31-64

  Godin, Biana ^a   P Driessen, Wouter H ^b   Proneth, Bettina ^b   Lee, Sei Young ^a,c   Srinivasan, Srimeenakshi ^a   Rumbaut, Rolando ^d   Arap, Wadih ^b   Pasqualini, Renata ^b   Ferrari, Mauro ^a,b,e   Decuzzi, Paolo ^a,f  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c The University of Texas at Austin   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e RICE UNIVERSITY   (United States)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; NANOPARTICLE;

BIOLOGICAL MODEL; CHEMISTRY; DIAGNOSTIC IMAGING; METHODOLOGY; PARTICLE SIZE; REVIEW; SURFACE PROPERTY;

DIAGNOSTIC IMAGING; MODELS, BIOLOGICAL; NANOPARTICLES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 77949572671     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2660(10)69009-8     Document Type: Book

References (124)

1. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., Weiner L.M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001, 61:4750.
2. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Drug. Discov. 2002, 2:750.
3. Allen T.M., Ahmad I., Lopes de Menezes D.E., Moase E.H. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem. Soc. Trans. 1995, 23:1073-1079.
4. Allen T.M., Sapra P., Moase E., Moreira J., Iden D. Adventures in targeting. J. Liposome Res. 2002, 12:5-12.
5. Amiji M.M. Nanotechnology for cancer therapy. 2007, CRC press, Boca Raton, FL, pp. 258-260.
6. Andersson L., Davies J., Duncan R., Ferruti P., Ford J., Kneller S., Mendichi R., Pasut G., Schiavon O., Summerford C., Tirk A., Veronese F.M., Vincenzi V., Wu G. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: Synthesis and evaluation as anticancer conjugates. Biomacromolecules 2005, 6:914-926.
7. Banerjee R.K., van Osdol W., Bungay P.M., Sung C., Dedrick R.L. Finite element model of antibody penetration in a prevascular tumor nodule embedded in normal tissue. J. Control. Release 2001, 74:193.
8. Barth H.G. Modern Methods of Particle Size Analysis. Vol. 73 1984, Wiley-Interscience.
9. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004, 56:1649.
10. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. USA 2006, 103:4930-4934.
11. Decuzzi P., Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 2006, 27:5307-5314.
12. Decuzzi P., Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 2007, 28:2915-2922.
13. Decuzzi P., Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 2008, 29:377-384.
14. Decuzzi P., Lee S., Decuzzi M., Ferrari M. Adhesion of microfabricated particles on vascular endothelium: A parametric analysis. Ann. Biomed. Eng. 2004, 32:793-802.
15. Decuzzi P., Lee S., Bhushan B., Ferrari M. A theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 2005, 33:179-190.
16. Decuzzi P., Gentile F., Granaldi A., Curcio A., Causa F., Indolfi C., Netti P., Ferrari M. Flow chamber analysis of size effects in the adhesion of spherical particles. Int. J. Nanomed. 2007, 2:689-696.
17. Decuzzi P., Pasqualini R., Arap W., Ferrari M. Intravascular delivery of particulate systems: Does geometry really matter?. Pharm. Res. 2009, 2009:26235-26243.
18. Diagaradjane P., Orenstein-Cardona J.M., Colon-Casasnovas N.E., Deorukhkar A., Shentu S., Kuno N., Schwartz D.L., Gelovani J.G., Krishnan S. Imaging epidermal growth factor receptor expression in vivo: Pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin. Cancer Res. 2008, 14:731-741.
19. Donaldson K., Borm P. Particle Toxicology 2007, CRC Press, Boca Raton, FL, pp. 49-56.
20. Douziech-Eyrolles L., Marchais H., Herve K., Munnier E., Souce M., Linassier C., Dubois P., Chourpa I. Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int. J. Nanomed. 2007, 2:541.
21. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51:691.
22. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2:347.
23. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688.
24. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006, 103:6315.
25. Farokhzad O.C., Karp J.M., Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Exp. Opin. Drug Deliv. 2006, 3:311.
26. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
27. Ferrari M. Nanovector therapeutics. Curr. Opin. Chem. Biol. 2005, 9:343.
28. Ferrari M. Nanogeometry: Beyond drug delivery. Nat. Nanotechnol. 2008, 3:131.
29. Fung Y.C. Biomechanics: Mechanical Properties of Living Tissues 1993, Springer, New York, US.
30. Gentile F., Chiappini C., Fine D., Bhavane R.C., Peluccio M.S., Cheng M.M., Liu X., Ferrari M., Decuzzi P. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J. Biomech. 2008, 41:2312-2318.
31. Gentile F., Curcio A., Indolfi C., Ferrari M., Decuzzi P. The margination propensity of spherical particles for vascular targeting in the microcirculation. J. Nanobiotechnol. 2008, 6:9.
32. Goldman A.J.R., Cox G., Brenner H. Slow viscous motion of a sphere parallel to a plane wall II. Couette flow. Chem. Eng. Sci. 1967, 22:635-660.
33. Goldsmith H.L., Spain S. Margination of leukocytes in blood flow through small tubes. Microvasc. Res. 1984, 27:204-222.
34. Goren D., Horowitz A.T., Zalipsky S., Woodle M.C., Yarden Y., Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies. Br. J. Cancer 1996, 74:1749.
35. Gotoh K., Masuda H., Higashitani K. Powder Technology Handbook 1997, Marcel Dekker, New York, US, (pp. 43-55).
36. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794.
37. Hajitou A., Pasqualini R., Arap W. Vascular targeting: Recent advances and therapeutic perspectives. Trends Cardiovasc. Med. 2006, 16:80-88.
38. Hajitou A., Trepel M., Lilley C.E., Soghomonyan S., Alauddin M.M., Marini F.C., Restel B.H., Ozawa M.G., Moya C.A., Rangel R., Sun Y., Zaoui K., et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006, 125:385.
39. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2:214.
40. Harris N.R., Whitt S.P., Zilberberg J., Alexander J.S., Rumbaut R.E. Extravascular transport of fluorescently labeled albumins in the rat mesentery. Microcirculation 2002, 9:177-187.
41. Heath J.R., Davis M.E. Nanotechnology and cancer. Annu. Rev. Med. 2008, 59:251.
42. Herant M., Heinrich V., Dembo M. Mechanics of neutrophil phagocytosis: Experiments and quantitative models. J. Cell Sci. 2006, 119:1903-1913.
43. Hirsch L.R., Stafford R.J., Bankson J.A., Sershen S.R., Rivera B., Price R.E., Hazle J.D., Halas N.J., West J.L. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. USA 2003, 100:13549.
44. Hofheinz R.D., Gnad-Vogt S.U., Beyer U., Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005, 16:691.
45. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
46. Hosokawa S., Tagawa T., Niki H., Hirakawa Y., Nohga K., Nagaike K. Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br. J. Cancer 2003, 89:1545-1551.
47. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6:559-594.
48. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1:241-263.
49. Jain R.K., Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res. 1988, 48:7022-7032.
50. Jiang W., Kim B.Y., Rutka J.T., Chan W.C. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 2008, 3:145-150.
51. Juweid M., Neumann R., Paik C., Perez-Bacete M.J., Sato J., van Osdol W., Weinstein J.N. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier. Cancer Res. 1992, 52:5144.
52. Kang J., Lee M.S., Copland J.A., Luxon B.A., Gorenstein D.G. Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-beta1 protein. Bioorg. Med. Chem. Lett. 2008, 18:1835.
53. Kim S., Kong R.L., Popel A.S., Intaglietta M., Johnson P.C. Temporal and spatial variations of cell-free layer width in arterioles. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1526-H1535.
54. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1991, 1062:142.
55. Korgel B.A., Zanten J.H., Monbouquette H.G. Vesicle size distributions measured by flow field-flow fractionation coupled with multiangle light scattering. Biophys. J. 1998, 74:3264-3272.
56. Koval M., Preiter K., Adles C., Stahl P.D., Steinberg T.H. Size of IgG-opsonized particles determines macrophage response during internalization. Exp. Cell Res. 1998, 242:265-273.
57. Langer R. Drug delivery and targeting. Nature 1998, 392:5.
58. Lee S.Y., Ferrari M., Decuzzi P. Design of bio-mimetic particles with enhanced vascular interaction. J. Biomech. 2009, 42(12):1885-1890.
59. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
60. Levy-Nissenbaum E., Radovic-Moreno A.F., Wang A.Z., Langer R., Farokhzad O.C. Nanotechnology and aptamers: Applications in drug delivery. Trends Biotechnol. 2008, 26:442-449.
61. Li Z., Rumbaut R.E., Burns A.R., Smith C.W. Platelet response to corneal abrasion is necessary for acute inflammation and efficient re-epithelialization. Invest. Ophthalmol. Vis. Sci. 2006, 47:4794-4802.
62. Li Z., Burns A.R., Rumbaut R.E., Smith C.W. g/d T cells are necessary for platelet and neutrophil accumulation in limbal vessels and efficient epithelial repair after corneal abrasion. Am. J. Pathol. 2007, 171:838-845.
63. Lopes de Menezes D.E., Pilarski L.M., Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998, 58:3320-3330.
64. Maeda H., Noguchi Y., Sato K., Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 1994, 85:331-334.
65. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 2000, 65:271.
66. Maeda H., Fang J., Inutsuka T., Kitamoto Y. Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int. Immunopharmacol. 2003, 3:319-328.
67. Marchio S., Lahdenranta J., Schlingemann R.O., Valdembri D., Wesseling P., Arap M.A., Hajitou A., Ozawa M.G., Trepel M., Giordano R.J., Nanus D.M., Dijkman H.B., et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer cell 2004, 5:151-162.
68. Mohammed A.R., Weston N., Coombes A.G., Fitzgerald M., Perrie Y. Liposome formulation of poorly water soluble drugs: Optimisation of drug loading and ESEM analysis of stability. Int. J. Pharm. 2004, 285(1-2):23-34.
69. Monsky W.L., Kruskal J.B., Lukyanov A.N., Girnun G.D., Ahmed M., Gazelle G.S., Huertas J.C., Stuart K.E., Torchilin V.P., Goldberg S.N. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology 2002, 224:823.
70. Muro S., Garnacho C., Champion J.A., Leferovich J., Gajewski C., Schuchman E.H., Mitragotri S., Muzykantov V.R. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol. Ther. 2008, 16:1450-1458.
71. Neofytou P. Comparison of blood rheological models for physiological flow simulation. Biorheology 2004, 41(6):693-714.
72. Neri D., Bicknell R. Tumour vascular targeting. Nat. Rev. Cancer 2005, 5:436-446.
73. Nie S., Kim G.J., Xing Y., Simons J.W. Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng. 2007, 9:257.
74. Ozawa M.G., Zurita A.J., Dias-Neto E., Nunes D.N., Sidman R.L., Gelovani J.G., Arap W., Pasqualini R. Beyond receptor expression levels: The relevance of target accessibility in ligand-directed pharmacodelivery systems. Trends Cardiovasc. Med. 2008, 18:126-132.
75. Pardridge W.M. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug. Chem. 2008, 19:1327-1338.
76. Park S., Yoo H.S. In vivo and in vitro anti-cancer activities and enhanced cellular uptakes of EGF fragment decorated doxorubicin nano-aggregates. Int. J. Pharm. 2010, 383:178-185.
77. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.
78. Parveen S., Sahoo S.K. Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs. Clin. Pharmacokinet. 2006, 45:965.
79. Pasqualini R., Koivunen E., Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J. Cell Biol. 1995, 130:1189-1196.
80. Pasqualini R., Koivunen E., Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 1997, 15:542-546.
81. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000, 60:722-727.
82. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., Allen T.M., Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 2006, 66:10073-10082.
83. Peer D., Karp J.M., Hong S.Y., Farokhzad O., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751.
84. Peltonen L., Hirvonen J. Physicochemical characterisation of nano- and microparticles. Curr. Nanosci. 2008, 4(1):101-107.
85. Philippot J.R., Schuber F. Liposomes as Tolls in Basic Research and Industry 1995, CRC press, Boca Raton, FL.
86. Ravnic D.J., Zhang Y.Z., Turhan A., Tsuda A., Pratt J.P., Huss H.T., Mentzer S.J. Biological and optical properties of fluorescent nanoparticles developed for intravascular imaging. Microsc. Res. Tech. 2007, 70:776-781.
87. Rejman J., Oberlem V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 2004, 377:159-169.
88. Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H. Nanomedicine-Developments and perspectives. Angew. Chem. Int. Ed. 2008, 48:872-897.
89. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. 1975, 51:135.
90. Rumbaut R.E., Huxley V.H. Similar permeability responses to nitric oxide synthase inhibitors of venules from three animal species. Microvasc. Res. 2002, 64:21-31.
91. Rumbaut R.E., Wang J., Huxley V.H. Differential effects of L-NAME on rat venular hydraulic conductivity. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H2017-H2023.
92. Rumbaut R.E., Randhawa J.K., Smith C.W., Burns A.R. Mouse cremaster venules are predisposed to light/dye-induced thrombosis independent of wall shear rate. CD18. ICAM-1. or P-selectin. Microcirculation 2004, 11:239-247.
93. Rumbaut R.E., Slaaf D.W., Burns A.R. Microvascular thrombosis models in venules and arterioles in vivo. Microcirculation 2005, 12:259-274.
94. Ruozi B., Tosi G., Forni F., Fresta M., Vandelli M.A. Atomic force microscopy and photon correlation spectroscopy: Two techniques for rapid characterization of liposomes. Eur. J. Pharm. Sci. 2005, 25(1):81-89.
95. Sakamoto J., Annapragada A., Decuzzi P., Ferrari M. Antibiological barrier nanovector technology for cancer applications. Expert Opin. Drug Deliv. 2007, 4:359.
96. Sanhai W.R., Sakamoto J.H., Canady R., Ferrari M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008, 3:242.
97. Sapra P., Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid. Res. 2003, 42:439-462.
98. Sapra P., Tyagi P., Allen T.M. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv. 2005, 2:369-381.
99. Saul J.M., Annapragada A.V., Bellamkonda R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control. Release 2006, 114:277.
100. Schroeder A., Avnir Y., Weisman S., Najajreh Y., Gabizon A., Talmon Y., Kost J., Barenholz Y. Controlling liposomal drug release with low frequency ultrasound: Mechanism and feasibility. Langmuir 2007, 23:4019.
101. Scott R.C., Rosano J.M., Ivanov Z., Wang B., Chong P.L., Issekutz A.C., Crabbe D.L., Kiani M.F. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J 2009, 23:3361-3367.
102. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
103. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568.
104. Sergeeva A., Kolonin M.G., Molldrem J.J., Pasqualini R., Arap W. Display technologies: Application for the discovery of drug and gene delivery agents. Adv. Drug Deliv. Rev. 2006, 58:1622-1654.
105. Seymour L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9:135-187.
106. Sharan M., Popel A.S. A two-phase model for flow of blood in narrow tubes with increased effective viscosity near the wall. Biorheology 2001, 38:415-428.
107. Smith M.L., Long D.S., Damiano E.R., Ley K. Near-wall micro-PIV reveals a hydrodynamically relevant endothelial surface layer in venules in vivo. Biophys. J. 2003, 85:637-645.
108. Souza G.R., Christianson D.R., Staquicini F.I., et al. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc. Natl. Acad. Sci. USA 2006, 103:1215.
109. Souza G.R., Yonel-Gumruk E., Fan D., Easley J., Rangel R., Guzman-Rojas L., Miller J.H., Arap W., Pasqualini R. Bottom-up assembly of hydrogels from bacteriophage and Au nanoparticles: The effect of cis- and trans-acting factors. PLoS One 2008, 3:e2242.
110. Stolnik S., Illum L., Davis S.S. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev. 1995, 16:195-214.
111. Tasciotti E., Liu X., Bhavane R., Plant K., Leonard A.D., Price B.K., Cheng M.M., Decuzzi P., Tour J.M., Robertson F.M., Ferrari M. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 2008, 3:151.
112. Temming K., Schiffelers R.M., Molema G., Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 2005, 8:381-402.
113. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145.
114. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9:E128.
115. Tyle P., Ram B.P. Monoclonal antibodies, immunoconjugates, and liposomes as targeted therapeutic systems. Targeted Diagn. Ther. 1990, 3:3-22.
116. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 1999, 5:83.
117. Vink H., Duling B.R. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ. Res. 1996, 79:581-589.
118. Vyas S.P., Sihorkar V. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. Adv. Drug Deliv. Rev. 2000, 43:101-164.
119. Wang A.Z., Gu F., Zhang L., Chan J.M., Radovic-Moreno A., Shaikh M.R., Farokhzad O.C. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther. 2008, 8:1063-1070.
120. Welsh D.G., Jackson W.F., Segal S.S. Oxygen induces electromechanical coupling in arteriolar smooth muscle cells: A role for L-type Ca2+ channels. Am. J. Physiol. 1998, 274:H2018-H2024.
121. Yang X., Wang H., Beasley D.W., Volk D.E., Zhao X., Luxon B.A., Lomas L.O., Herzog N.K., Aronson J.F., Barrett A.D., Leary J.F., Gorenstein D.G. Selection of thioaptamers for diagnostics and therapeutics. Ann. N. Y. Acad. Sci. 2006, 116:1082.
122. Zhang Y., Schlachetzki F., Pardridge W.M. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 2003, 7:11-18.
123. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 2007, 83:761.
124. Zuidam N.J., de Vruch R., Crommelin D.J.A. Liposomes 2003, 31-77. Oxford University Press, New York. V.P. Torchilin, V. Weissing (Eds.).